Safety and efficacy of the NVX-CoV2373 coronavirus disease 2019 vaccine at completion of the placebo-controlled phase of a randomized controlled trial by Heath, PT, Galiza, EP, Baxter, DN, Boffito, M, Browne, D, Burns, F, Chadwick, DR, Clark, R, Cosgrove, CA, Galloway, J, Goodman, AL, Heer, A, Higham, A, Iyengar, S, Jeanes, C, Kalra, PA, Kyriakidou, C, Bradley, JM, Munthali, C, Minassian, AM, McGill, F, Moore, P, Munsoor, I, Nicholls, H, Osanlou, O, Packham, J, Pretswell, CH, San Francisco Ramos, A, Saralaya, D, Sheridan, RP, Smith, R, Soiza, RL, Swift, PA, Thomson, EC, Turner, J, Viljoen, ME, Fries, L, Cho, I, McKnight, I, Glenn, G, Rivers, EJ, Robertson, A, Alves, K, Smith, K, Toback, S